Background: Amyloid-related imaging abnormalities (ARIA) have been reported with some anti-amyloid-β (Aβ) immunotherapy trials. They are detected with magnetic resonance imaging (MRI) and thought to represent transient accumulation of fluid/edema (ARIA-E) or microhemorrhages (ARIA-H). Although the clinical significance and pathophysiology are unknown, it has been proposed that anti-Aβimmunotherapy may affect blood-brain barrier (BBB) integrity.
Objective: To examine vascular integrity in aged (12–16 months) PDAPP and wild type mice (WT), we performed a series of longitudinal in vivo MRI studies.
Methods: Mice were treated on a weekly basis using anti-Aβimmunotherapy (3D6) and follow up was done longitudinally from 1–12 weeks after treatment. BBB-integrity was assessed using both visual assessment of T1-weighted scans and repeated T1 mapping in combination with gadolinium (Gd-DOTA).
Results: A subset of 3D6 treated PDAPP mice displayed numerous BBB disruptions, whereas WT and saline-treated PDAPP mice showed intact BBB integrity under the conditions tested. In addition, the contrast induced decrease in T1 value was observed in the meningeal and midline area. BBB disruption events occurred early during treatment (between 1 and 5 weeks), were transient, and resolved quickly. Finally, BBB-leakages associated with microhemorrhages were confirmed by Perls’Prussian blue histopathological analysis.
Conclusion: Our preclinical findings support the hypothesis that 3D6 leads to transient leakage from amyloid-positive vessels. The current study has provided valuable insights on the time course of vascular alterations during immunization treatment and supports further research in relation to the nature of ARIA and the utility of in vivo repeated T1 MRI as a translational tool.
KarranE, MerckenM, De StrooperB (2011) The amyloid cascade hypothesis for Alzheimer’s disease: An appraisal for the development of therapeutics. Nat Rev Drug Discov10, 698–712.
JanusC, PearsonJ, McLaurinJ, MathewsPM, JiangY, SchmidtSD, ChishtiMA, HorneP, HeslinD, FrenchJ, MountHT, NixonRA, MerckenM, BergeronC, FraserPE, St George-HyslopP, WestawayD (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s disease. Nature408, 979–982.
4.
MorganD, DiamondDM, GottschallPE, UgenKE, DickeyC, HardyJ, DuffK, JantzenP, DiCarloG, WilcockD, ConnorK, HatcherJ, HopeC, GordonM, ArendashGW (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature408, 982–985.
5.
BardF, CannonC, BarbourR, BurkeRL, GamesD, GrajedaH, GuidoT, HuK, HuangJ, Johnson-WoodK, KhanK, KholodenkoD, LeeM, LieberburgI, MotterR, NguyenM, SorianoF, VasquezN, WeissK, WelchB, SeubertP, SchenkD, YednockT (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med6, 916–919.
6.
WilcockDM, RojianiA, RosenthalA, SubbaraoS, FreemanMJ, GordonMN, MorganD (2004) Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation1, 24.
7.
MasliahE, HansenL, AdameA, CrewsL, BardF, LeeC, SeubertP, GamesD, KirbyL, SchenkD (2005) Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology64, 129–131.
8.
BocheD, ZotovaE, WellerRO, LoveS, NealJW, PickeringRM, WilkinsonD, HolmesC, NicollJA (2008) Consequence of Abeta immunization on the vasculature of human Alzheimer’s disease brain. Brain131, 3299–3310.
9.
ZagoW, ButtiniM, ComeryTA, NishiokaC, GardaiSJ, SeubertP, GamesD, BardF, SchenkD, KinneyGG (2012) Neutralization of soluble, synaptotoxic amyloid beta species by antibodies is epitope specific. J Neurosci32, 2696–2702.
10.
SallowayS, SperlingR, BrashearHR (2014) Phase 3 trials of solanezumab and bapineuzumab for Alzheimer’s disease. N Engl J Med370, 1460.
11.
OstrowitzkiS, DeptulaD, ThurfjellL, BarkhofF, BohrmannB, BrooksDJ, KlunkWE, AshfordE, YooK, XuZX, LoetscherH, SantarelliL (2012) Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol69, 198–207.
12.
SperlingRA, JackCRJr, BlackSE, FroschMP, GreenbergSM, HymanBT, ScheltensP, CarrilloMC, ThiesW, BednarMM, BlackRS, BrashearHR, GrundmanM, SiemersER, FeldmanHH, SchindlerRJ (2011) Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimers Dement7, 367–385.
13.
BlackRS, SperlingRA, SafirsteinB, MotterRN, PallayA, NicholsA, GrundmanM (2010) A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord24, 198–203.
14.
MorethJ, MavoungouC, SchindowskiK (2013) Passive anti-amyloid immunotherapy in Alzheimer’s disease: What are the most promising targets?Immun Ageing10, 18.
15.
SperlingR, SallowayS, BrooksDJ, TampieriD, BarakosJ, FoxNC, RaskindM, SabbaghM, HonigLS, PorsteinssonAP, LieberburgI, ArrighiHM, MorrisKA, LuY, LiuE, GreggKM, BrashearHR, KinneyGG, BlackR, GrundmanM (2012) Amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with bapineuzumab: A retrospective analysis. Lancet Neurol11, 241–249.
16.
ZagoW, SchroeterS, GuidoT, KhanK, SeubertP, YednockT, SchenkD, GreggKM, GamesD, BardF, KinneyGG (2013) Vascular alterations in PDAPP mice after anti-Abeta immunotherapy: Implications for amyloid-related imaging abnormalities. Alzheimers Dement9(5 Suppl), S105–S115.
WilcockDM, ColtonCA (2009) Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice. CNS Neurol Disord Drug Targets8, 50–64.
19.
WellerRO, SubashM, PrestonSD, MazantiI, CarareRO (2008) Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer’s disease. Brain Pathol18, 253–266.
20.
ZlokovicBV, DeaneR, SagareAP, BellRD, WinklerEA (2010) Low-density lipoprotein receptor-related protein-1: A serial clearance homeostatic mechanism controlling Alzheimer’s amyloid beta-peptide elimination from the brain. J Neurochem115, 1077–1089.
21.
RakicP (2009) Evolution of the neocortex: A perspective from developmental biology. Nat Rev Neurosci10, 724–735.
HarrisNG, GaudenV, FraserPA, WilliamsSR, ParkerGJ (2002) MRI measurement of blood-brain barrier permeability following spontaneous reperfusion in the starch microsphere model of ischemia. Magn Reson Imaging20, 221–230.
24.
LundH, KrakauerM, SkimmingeA, SellebjergF, GardeE, SiebnerHR, PaulsonOB, HesseD, HansonLG (2013) Blood-brain barrier permeability of normal appearing white matter in relapsing-remitting multiple sclerosis. PLoS One8, e56375.
25.
EssigM, DinkelJ, GutierrezJE (2012) Use of contrast media in neuroimaging. Magn Reson Imaging Clin N Am20, 633–648.
26.
van VlietEA, OtteWM, GorterJA, DijkhuizenRM, WadmanWJ (2014) Longitudinal assessment of blood-brain barrier leakage during epileptogenesis in rats. A quantitative MRI study. Neurobiol Dis63, 74–84.
27.
Johnson-WoodK, LeeM, MotterR, HuK, GordonG, BarbourR, KhanK, GordonM, TanH, GamesD, LieberburgI, SchenkD, SeubertP, McConlogueL (1997) Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci U S A94, 1550–1555.
28.
MontagneA, TogaAW, ZlokovicBV (2016) Blood-brain barrier permeability and gadolinium: Benefits and potential pitfalls in research. JAMA Neurol73, 13–14.
29.
BowmanGL, QuinnJF (2008) Alzheimer’s disease and the blood-brain barrier: Past, present and future. Aging Health4, 47–55.
30.
EricksonMA, BanksWA (2013) Blood-brain barrier dysfunction as a cause and consequence of Alzheimer’s disease. J Cereb Blood Flow Metab33, 1500–1513.
31.
GreenbergSM, VernooijMW, CordonnierC, ViswanathanA, Al-Shahi SalmanR, WarachS, LaunerLJ, Van BuchemMA, BretelerMM, Microbleed StudyG (2009) Cerebral microbleeds: A guide to detection and interpretation. Lancet Neurol8, 165–174.
32.
BeckmannN, GerardC, AbramowskiD, CannetC, StaufenbielM (2011) Noninvasive magnetic resonance imaging detection of cerebral amyloid angiopathy-related microvascular alterations using superparamagnetic iron oxide particles in APP transgenic mouse models of Alzheimer’s disease: Application to passive Abeta immunotherapy. J Neurosci31, 1023–1031.
33.
GoodmanJF, FreemanG, AngusW, BrownT, Cheng-te ChouP, BalesK (2012) Spontaneous amyloid-related imaging abnormalities of the microhemorrage and effusive/edematous types in aged APP+presenilin 1 mice.P11-P. Alzheimers Dement8(Suppl), 12.
34.
SimonJH (1997) Contrast-enhanced MR imaging in the evaluation of treatment response and prediction of outcome in multiple sclerosis. J Magn Reson Imaging7, 29–37.
35.
HelbichTH, RobertsTP, GossmannA, WendlandMF, ShamesDM, AdachiM, YangS, HuberS, DaldrupH, BraschRC (2000) Quantitative gadopentetate-enhanced MRI of breast tumors: Testing of different analytic methods. Magn Reson Med44, 915–924.
36.
KaiserWA, ZeitlerE (1989) MR imaging of the breast: Fast imaging sequences with and without Gd-DTPA. Preliminary observations. Radiology170, 681–686.
37.
MaedaM, MaleyJE, CrosbyDL, QuetsJP, ZhuMW, LeeGJ, LawlerGJ, UedaT, BendixenBH, YuhWT (1997) Application of contrast agents in the evaluation of stroke: Conventional MR and echo-planar MR imaging. J Magn Reson Imaging7, 23–28.
38.
van de HaarHJ, BurgmansS, HofmanPA, VerheyFR, JansenJF, BackesWH (2015) Blood-brain barrier impairment in dementia: Current and future in vivo assessments. Neurosci Biobehav Rev49, 71–81.
39.
MontagneA, BarnesSR, SweeneyMD, HallidayMR, SagareAP, ZhaoZ, TogaAW, JacobsRE, LiuCY, AmezcuaL, HarringtonMG, ChuiHC, LawM, ZlokovicBV (2015) Blood-brain barrier breakdown in the aging human hippocampus. Neuron85, 296–302.
